GENOMICS LIMITED

1. GENOMICS LIMITED 2024-11-07 → present
2. GENOMICS PLC 2015-03-30 → 2024-11-07
3. GENOMICS LIMITED 2014-01-10 → 2015-03-30

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

KPMG LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors have considered the Group's liquidity position. At 31 December 2024 the Group had net assets of £26,582,598 (2023: £2,273,644). The Group is investor funded and has sufficient funding in place to secure the business beyond the going concern consideration timeframe of 12 months from the date of signature of the financial statements. At 31 December 2024, the Group held cash at bank and in hand of £23,489,258 (2023: £4,921,058). The Group's financial forecasts use severe, but plausible assumptions that there will be a continuation of securing commercial contracts with existing and new customers through the going concern timeframe. Business is forecast to continue as planned through the next 12 months, with activities and revenue projected to continue materially as planned. To mitigate the risks outside of the Group's control, the Directors have a number of measures in place including, but not limited to, monthly review of actual results vs budget, carefully considered annual pay increases for employees, scrutiny of new hire positions in advance of recruitment and ongoing critical review of general expenditure. In addition, the Directors are confident that they have the ability to flex and reduce operating expenses in future months if necessary. The Directors take further comfort from the fact that the Group has been able to attract substantial additional funding from existing and new investors in its most recent funding round. Consequently, the Directors are confident that the Group will have sufficient funds to continue to meet its liabilities as they fall due for at least 12 months from the date of approval of the financial statements and therefore have prepared the financial statements on a going concern basis.”

Group structure

1. GENOMICS LIMITED · parent
   1. Genomics Inc. 100% · Wilmington, New Castle, DE 19801 · The principal activity of Genomics Inc. is the same as that of the parent Company.

Significant events

• “On 7 November 2024, the company re-registered from a public company to a private company. Consequently, the company name has changed from Genomics plc to Genomics Limited.”
• “The Group had no capital commitments at 31 December 2024 (2023: none).”
• “There are no reportable post balance sheet events.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

10

last 12 months

Capital events

8

last 24 months

Officers appointed

2

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.